Correvio Pharma (CORV) Misses Q1 EPS by 3c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Correvio Reports First Quarter 2019 Financial Results
May 8, 2019 8:00 AM EDTMark H.N. Corrigan, MD Commences Role as CEO, effective March 14, 2019
Company on Track to Resubmit Brinavess NDA in Q2 2019
Management to Host Conference Call and Webcast Today, May 8, 2019 at 8:30 a.m. Eastern (5:30 a.m. Pacific)
NASDAQ: CORVÂ TSX: CORV
VANCOUVER, May 8, 2019 /PRNewswire/ -Â Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today reported financial results for its first quarter ended March 31, 2019 and commented on recent... More
